Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2006-06-27
2006-06-27
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C530S387100, C530S388250
Reexamination Certificate
active
07067313
ABSTRACT:
The present invention comprises ligands and methods of manufacture thereof as well as pharmaceutical preparations including the ligands. The ligands may be human or humanized monoclonal antibodies and fragments, derivatives and homologs thereof. These may exhibit an unforeseen “plateau effect”, i.e. the achievement of only a partial inactivation of a factor involved in hemostasis, in particular in the coagulation cascade, either individually or in combination even in molar excess. The ligands may bind to a factor or a complex of factors resulting in only partially impairing the function of a physiologically functional site of the said factor or factor complex even in molar excess. This makes the ligands particularly suitable for treating coagulation disorders and resulting thrombotic pathologic conditions while minimizing the risk of bleeding. Particularly useful is a property of ligands in accordance with the present invention to allow some physiological function of the affected site even when the ligand is in molar excess. The ligands may be anti-factor VIII antibodies or antibodies against a factor VIII complex, in particular human or human hybrid monoclonal antibodies which bind to factor VIII or a factor VIII complex and at least partially inhibit the activity of factor VIII.
REFERENCES:
patent: 5602015 (1997-02-01), Sudhir
patent: 5744446 (1998-04-01), Lollar et al.
patent: 6210675 (2001-04-01), Highfield et al.
patent: WO 97 26010 (1997-07-01), None
Lenting et al. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J. Biol Chem 269(10):7150-7155, 1994.
Peerlinck et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood. 93(7):2267-2273, Apr. 1999.
Gilles et al. Mutation Arg2150-His in the factor VIII C1 domain alters the binding of factor VIII to von Willebrand factor and is responsible for a mild hemophilia A phenotype. Blood vol. 92, 10Suppl. 1 Part 1-2, pp. 710., Nov. 15, 1998.
J. Batlle et al. : “Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.” Annals of Hematology, vol. 75, No. 3, Sep. 1997, pp. 111-115, XP 000906715.
J. Ingerslev et al.: “Applications of immunoperoxidase techniques in specificity testing of monoclonal antibodies (Mabs) against von Willebrand factor (vWF).” Clinica Chemica Acta, vol. 174, No. 1, 1988, pp. 65-82, XP000906709.
M. Gawryl et al.: “Inactiviation of factor VIII coagulant activity by two different types of human antibodies.” BLOOD, vol. 60, No. 5, Nov. 1982, pp. 1103-1109, XP000892192.
B. Ly et. al.: “Characterization of an antibody to factor VIII in a patient with acquired hemophilia with circulating immune complexes.” Scandinavian Journal of Haematology, vol. 28, No. 2, Feb. 1982, pp. 132-140, XP000892196.
M. Jacquemin et al.: “Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.” BLOOD, vol. 92, No. 2, Jul. 15, 1998, pp. 496-506, XP000906844.
M Jacquemin et al.: “A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.” BLOOD, vol. 95, No. 1, Jan. 1, 2000, pp. 156-163, XP002150704.
Jacquemin Marc G.
Saint-Remy Jean-Marie R.
Chan Christina
Clark & Elbing LLP
D. Collen Research Foundation
Haddad Maher
LandOfFree
Ligands for use in therapeutic compositions for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ligands for use in therapeutic compositions for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligands for use in therapeutic compositions for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3637158